For the year ending 2025-12-31, VCYT had $123,595K increase in cash & cash equivalents over the period. $126,630K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenue | 517,145 |
| Laboratory supplies and reagents expense | 57,284 |
| Sample collection expense | 12,436 |
| Compensation expense | 24,611 |
| Other cost | 19,655 |
| Allocation of facilities and it expenses | 13,576 |
| Cost of revenue-Testing | 127,562 |
| Product costs | 3,787 |
| License fees and royalties | 1,206 |
| Other cost | 3,348 |
| Allocation of facilities and it expenses | 466 |
| Cost of revenue-Product | 8,807 |
| Compensation expense | 3,320 |
| Other cost | 3,333 |
| Allocation of facilities and it expenses | 925 |
| Cost of revenue-Biopharmaceutical And Other | 7,578 |
| Intangible asset amortization - cost of revenue | 10,666 |
| Gross profit | 362,532 |
| Compensation expense | 37,784 |
| Direct research and development expense | 16,596 |
| Other research and development expenses | 8,492 |
| Allocation of facilities and it expenses | 7,942 |
| Research and development | 70,814 |
| Compensation expense | 69,209 |
| Direct research and development expense | 5,563 |
| Other selling and marketing expenses | 14,943 |
| Allocation of facilities and it expenses | 10,450 |
| Selling and marketing | 100,165 |
| Compensation expense | 82,909 |
| Other general and administrative expenses | 61,234 |
| Allocation of facilities and it expenses | -33,359 |
| General and administrative | 110,784 |
| Impairment of assets | 20,505 |
| Intangible asset amortization - operating expenses-Intangible Asset Amortization | 2,487 |
| Other income, net | 10,424 |
| Income tax provision (benefit) | 1,848 |
| Net income (loss) | 66,353 |
| Depreciation and amortization | 21,415 |
| Loss on disposal of property, plant and equipment | -15 |
| Stock-based compensation | 43,601 |
| Deferred income taxes | -581 |
| Non-cash lease expense | 2,991 |
| Revaluation of acquisition-related contingent consideration | -15,295 |
| Amortization of discount on short-term investments | 3,270 |
| Impairment loss | 20,505 |
| Non-cash loss on deconsolidation of subsidiary | -6,708 |
| Effect of foreign currency on operations | 3,834 |
| Accounts receivable | 708 |
| Supplies and inventory | 2,861 |
| Prepaid expenses and other current assets | 2,054 |
| Other assets | -525 |
| Operating lease liability | -2,480 |
| Accounts payable | -1,039 |
| Accrued liabilities and deferred revenue | 6,316 |
| Net cash provided by operating activities | 136,307 |
| Purchase of short-term investments | 149,998 |
| Proceeds from sale of short-term investments | 0 |
| Proceeds from maturity of short-term investments | 153,311 |
| Loss on deconsolidation of subsidiary - cash | 2,845 |
| Acquisition of c2i, net of cash acquired | 0 |
| Purchases of property, plant and equipment | 9,677 |
| Net cash (used in) provided by investing activities | -9,209 |
| Payment of contingent consideration for acquisition | 0 |
| Payment of taxes on vested restricted stock units | 18,304 |
| Proceeds from the exercise of common stock options and employee stock purchases | 14,082 |
| Net cash (used in) provided by financing activities | -4,222 |
| Increase in cash, cash equivalents and restricted cash | 122,876 |
| Effect of foreign currency on cash, cash equivalents and restricted cash | 719 |
| Net increase in cash, cash equivalents and restricted cash | 123,595 |
| Cash, cash equivalents and restricted cash at beginning of year | 240,631 |
| Cash, cash equivalents and restricted cash at end of year | 364,226 |
VERACYTE, INC. (VCYT)
VERACYTE, INC. (VCYT)